

# Christian Asseburg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1051173/publications.pdf>

Version: 2024-02-01

51  
papers

916  
citations

430874

18  
h-index

454955

30  
g-index

53  
all docs

53  
docs citations

53  
times ranked

1314  
citing authors

#	ARTICLE	IF	CITATIONS
1	Advantages in Management and Remote Monitoring of Intravenous Therapy: Exploratory Survey and Economic Evaluation of Gravity-Based Infusions in Finland. <i>Advances in Therapy</i> , 2022, , 1.	2.9	0
2	Exploring Structural Uncertainty and Impact of Health State Utility Values on Lifetime Outcomes in Diabetes Economic Simulation Models: Findings from the Ninth Mount Hood Diabetes Quality-of-Life Challenge. <i>Medical Decision Making</i> , 2022, 42, 599-611.	2.4	5
3	Macrovascular Risk Equations Based on the CANVAS Program. <i>Pharmacoeconomics</i> , 2021, 39, 447-461.	3.3	4
4	Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation. <i>ClinicoEconomics and Outcomes Research</i> , 2021, Volume 13, 745-755.	1.9	8
5	Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge. <i>Value in Health</i> , 2020, 23, 1163-1170.	0.3	32
6	Development and Internal Validation of a Discrete Event Simulation Model of Diabetic Kidney Disease Using CREDENCE Trial Data. <i>Diabetes Therapy</i> , 2020, 11, 2657-2676.	2.5	8
7	Challenges and Opportunities Associated with Incorporating New Evidence of Drug-Mediated Cardioprotection in the Economic Modeling of Type 2 Diabetes: A Literature Review. <i>Diabetes Therapy</i> , 2019, 10, 1753-1769.	2.5	11
8	Conducting and interpreting results of network meta-analyses in type 2 diabetes mellitus: A review of network meta-analyses that include sodium glucose co-transporter 2 inhibitors. <i>Diabetes Research and Clinical Practice</i> , 2019, 148, 222-233.	2.8	2
9	Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge. <i>Value in Health</i> , 2018, 21, 724-731.	0.3	63
10	Assessing the Value of Canagliflozin (CANA) vs. Sitagliptin (SITA) as Second-Line Therapy in the U.S.â€”The Importance of Considering Evidence from the CANVAS Program. <i>Diabetes</i> , 2018, 67, 1272-P.	0.6	3
11	Multivariate Prediction Equations for HbA 1c Lowering, Weight Change, and Hypoglycemic Events Associated with Insulin Rescue Medication in Type 2 Diabetes Mellitus: Informing Economic Modeling. <i>Value in Health</i> , 2017, 20, 357-371.	0.3	23
12	Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland. <i>Advances in Therapy</i> , 2017, 34, 2316-2332.	2.9	10
13	Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM). <i>Pharmacoeconomics</i> , 2017, 35, 375-396.	3.3	24
14	Correctly Capturing Uncertainty in Treatment Effects in Simulation Modeling. <i>Value in Health</i> , 2016, 19, A382.	0.3	0
15	Cost-Effectiveness Depends on the Subsequent Treatment Sequence: An Example from Multiple Sclerosis. <i>Value in Health</i> , 2016, 19, A375.	0.3	1
16	UPDATE OF THE MODEL VALIDATION OF THE ECONOMIC AND HEALTH OUTCOMES MODEL OF TYPE 2 DIABETES MELLITUS (ECHO-T2DM). <i>Value in Health</i> , 2016, 19, A88.	0.3	0
17	Warfarin treatment among Finnish patients with atrial fibrillation: retrospective registry study based on primary healthcare data. <i>BMJ Open</i> , 2014, 4, e004071.	1.9	21
18	Modelling the Persistence of Disease-Modifying Drug Treatment (DMT) and its Independent Drivers in Finnish Multiple Sclerosis (MS) Patients: Parametric Survival Modelling. <i>Value in Health</i> , 2014, 17, A400.	0.3	2

#	ARTICLE	IF	CITATIONS
19	Cost-Utility Analysis (cua) Of First-Line Disease-Modifying Treatments (DMT) Versus Best Supportive Care (Bsc) In Finnish Relapsing-Remitting Multiple Sclerosis (RRMS) Patients. Value in Health, 2014, 17, A399.	0.3	1
20	Current and Future Strategy for Osteoporosis Screening and Diagnostics: Cost-Effectiveness of Frax with or without Pulse-Echo Ultrasound Measurement of Bone Mineral Density and DXA on Demand. Value in Health, 2013, 16, A564-A565.	0.3	0
21	Cost-Effectiveness of Sequences of Biologic Treatments for Moderate-To-Severe Psoriasis in Finland. Value in Health, 2013, 16, A507-A508.	0.3	0
22	Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany. Clinical Research in Cardiology, 2013, 102, 447-458.	3.3	26
23	FRI0184â€¦Cost-effectiveness and budget impact of certolizumab pegol against the current mix of anti-tnf treatments in an outcomes-based risk-sharing scheme in finland. Annals of the Rheumatic Diseases, 2013, 72, A434.2-A434.	0.9	1
24	Validation of economic and health outcomes simulation model of type 2 diabetes mellitus (ECHO-T2DM). Journal of Medical Economics, 2013, 16, 1007-1021.	2.1	27
25	Hospitalisation Utilisation and Costs in Schizophrenia Patients in Finland before and after Initiation of Risperidone Long-Acting Injection. Schizophrenia Research and Treatment, 2012, 2012, 1-9.	1.5	14
26	Cost effectiveness of golimumab for the treatment of active psoriatic arthritis. European Journal of Health Economics, 2012, 13, 801-809.	2.8	16
27	COST-EFFECTIVENESS OF ORAL TRIPTANS FOR ACUTE MIGRAINE: MIXED TREATMENT COMPARISON. International Journal of Technology Assessment in Health Care, 2012, 28, 382-389.	0.5	8
28	The Cost-Effectiveness of Different Chemotherapy Strategies for Patients with Poor Prognosis Advanced Colorectal Cancer (MRC FOCUS). Value in Health, 2012, 15, 22-31.	0.3	6
29	PMS81 Cost-Effectiveness and Budget Impact of Certolizumab Pegol Against a Mix of Treatments in an Outcomes-Based Risk-Sharing Scheme in Finland. Value in Health, 2012, 15, A454.	0.3	0
30	Effectiveness and Cost-Effectiveness of Antidepressants in Primary Care: A Multiple Treatment Comparison Meta-Analysis and Cost-Effectiveness Model. PLoS ONE, 2012, 7, e42003.	2.5	46
31	Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: Cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial. Acta Oncologica, 2011, 50, 344-352.	1.8	41
32	Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis. Value in Health, 2011, 14, 15-23.	0.3	12
33	PCV70 Cost Effectiveness of Ticagrelor in the Treatment of Acute Coronary Syndrome in Germany. Value in Health, 2011, 14, A376-A377.	0.3	1
34	Cost-Effectiveness of Targeted Therapy With Cetuximab in Patients With K-ras Wild-Type Colorectal Cancer Presenting With Initially Unresectable Metastases Limited to the Liver in a German Setting. Clinical Therapeutics, 2011, 33, 482-497.	2.5	32
35	Costâ€¦effectiveness of a barrierâ€¦strengthening moisturizing cream as maintenance therapy vs. no treatment after an initial steroid course in patients with atopic dermatitis in Sweden â€” with model applications for Denmark, Norway and Finland. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 474-480.	2.4	17
36	Primary angioplasty versus thrombolysis for acute ST-elevation myocardial infarction: an economic analysis of the National Infarct Angioplasty project. Heart, 2010, 96, 668-672.	2.9	30

#	ARTICLE	IF	CITATIONS
37	PDB25 THE ECONOMIC IMPACT OF WEIGHT LOSS FOR PATIENTS WITH NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS (T2DM) IN THE US. Value in Health, 2010, 13, A59.	0.3	0
38	PMS34 COST-EFFECTIVENESS OF GOLIMUMAB IN PSORIATIC ARTHRITIS FROM THE UK PAYER PERSPECTIVE. Value in Health, 2010, 13, A308.	0.3	0
39	The Functional Response of a Generalist Predator. PLoS ONE, 2010, 5, e10761.	2.5	84
40	PMC38 VALIDATION OF THE IHE/J&J ECONOMIC SIMULATION MODEL OF TYPE-2 DIABETES MELLITUS (T2DM). Value in Health, 2009, 12, A26.	0.3	1
41	PSY15 THE IMPACT OF ADHERENCE ON THE COSTS AND BENEFITS OF INTENSIVE LIFESTYLE MANAGEMENT (ILM) IN OVERWEIGHT AND OBESE PATIENTS AT HIGH RISK FOR TYPE-2 DIABETES MELLITUS (T2DM). Value in Health, 2009, 12, A132.	0.3	0
42	PMH22 IMPACT ON SCHIZOPHRENIA INPATIENT RESOURCE USE FOLLOWING SWITCH TO LONG-ACTING RISPERIDONE IN FINLAND. Value in Health, 2008, 11, A586.	0.3	0
43	Assessing the effectiveness of primary angioplasty compared with thrombolysis and its relationship to time delay: a Bayesian evidence synthesis. Heart, 2007, 93, 1244-1250.	2.9	29
44	The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis. Rheumatology, 2007, 46, 1729-1735.	1.9	52
45	Preventive strategies for group B streptococcal and other bacterial infections in early infancy: cost effectiveness and value of information analyses. BMJ: British Medical Journal, 2007, 335, 655.	2.3	59
46	Is primary angioplasty cost effective in the UK? Results of a comprehensive decision analysis. Heart, 2007, 93, 1238-1243.	2.9	41
47	SENSITIVITY TO ASSUMPTIONS IN MODELS OF GENERALIST PREDATION ON A CYCLIC PREY. Ecology, 2007, 88, 2576-2586.	3.2	14
48	Prenatal screening and treatment strategies to prevent group B streptococcal and other bacterial infections in early infancy: cost-effectiveness and expected value of information analyses. Health Technology Assessment, 2007, 11, 1-226, iii.	2.8	64
49	The functional response of generalist predators and its implications for the monitoring of marine ecosystems. , 2006, , 262-274.		14
50	Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technology Assessment, 2006, 10, iii-iv, xiii-xvi, 1-239.	2.8	62
51	MC8 THE APPLICATION OF BAYESIAN METHODS TO EVALUATE THE IMPACT OF TIME-DELAY ON THE COST-EFFECTIVENESS OF PRIMARY ANGIOPLASTY FOR ACUTE MYOCARDIAL INFARCTION. Value in Health, 2005, 8, A18.	0.3	0